PHASE I STUDY OF ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT BRAIN TUMORS.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Anti-tenascin monoclonal antibody 81C6 I-131 (Primary)
- Indications Glioma
- Focus Adverse reactions; Therapeutic Use
- 16 Jul 2014 Biomarkers information updated
- 15 Feb 2013 Actual end date added to 1 Mar 2010 as reported by ClinicalTrials.gov.
- 13 Dec 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.